Filtered By:
Condition: Heart Attack
Countries: Canada Health

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 334 results found since Jan 2013.

Lipoprotein(a) variability over time in adult lipid clinic patients
Lipoprotein(a) (Lp[a]) is a low-density lipoprotein (LDL)-like particle in which apolipoprotein (apo) B is covalently bound to a plasminogen-like molecule called apo(a) [1]. Elevated plasma Lp(a) concentration is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, stroke and cardiac death [1]. The European Atherosclerosis Society, European Society of Cardiology and Canadian Cardiovascular Society (CCS) dyslipidemia guidelines recommend measurement of Lp(a) once in an individual's lifetime to identify patients with high levels who would benefit from earlier, more i...
Source: Atherosclerosis - September 5, 2022 Category: Cardiology Authors: Isabel Shamsudeen, Robert A. Hegele Tags: Correspondence Source Type: research

TransCarotid Revascularization With Dynamic Flow Reversal Versus Carotid Endarterectomy in the Vascular Quality Initiative Surveillance Project
Objective: To compare the outcomes of TCAR with flow reversal to the gold standard CEA using data from the Society for Vascular Surgery Vascular Quality Initiative TCAR Surveillance Project. Summary of Background Data: TCAR is a novel minimally invasive procedure for carotid revascularization in high-risk patients that is associated with significantly lower stroke rates compared with carotid artery stenting via the transfemoral approach. Methods: Patients in the United States and Canada who underwent TCAR and CEA for carotid artery stenosis (2016-2019) were included. Propensity scores were calculated base...
Source: Annals of Surgery - July 15, 2022 Category: Surgery Tags: Original Articles Source Type: research

Intravascular lithotripsy-assisted PCI for severely calcified coronary lesions: evaluating the impact on quality of life and outcomes
ConclusionsCoronary IVL is a safe and effective adjunctive therapy for treating heavily calcified coronary lesions. This cohort shows high procedural success and a significant reduction in CCS angina at follow-up.
Source: Irish Journal of Medical Science - July 9, 2022 Category: General Medicine Source Type: research

The impact of hypoalbuminemia on postoperative outcomes after outpatient surgery: a national analysis of the NSQIP database
CONCLUSIONS: Hypoalbuminemia is associated with major complications and death in outpatient surgery. Since hypoalbuminemia is a potential modifiable intervention, future clinical trials to evaluate the impact of optimizing preoperative albumin levels before outpatient surgery are warranted.PMID:35761062 | DOI:10.1007/s12630-022-02280-7
Source: Canadian Journal of Anaesthesia - June 27, 2022 Category: Anesthesiology Authors: Sean Curran Patricia Apruzzese Mark C Kendall Gildasio De Oliveira Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial
Introduction Sleep-time blood pressure correlates more strongly with adverse cardiovascular events than does daytime blood pressure. The BedMed trial evaluates whether bedtime antihypertensive administration, as compared with conventional morning use, reduces major adverse cardiovascular events. Methods and analysis Design Prospective randomised, open-label, blinded end-point trial. Participants Hypertensive primary care patients using blood pressure lowering medication and free from glaucoma. Setting Community primary care providers in 5 Canadian provinces (British Columbia, Alberta, Saskatchewan, Manitoba and Ontario) a...
Source: BMJ Open - February 24, 2022 Category: General Medicine Authors: Garrison, S. R., Kolber, M. R., Allan, G. M., Bakal, J., Green, L., Singer, A., Trueman, D. R., McAlister, F. A., Padwal, R. S., Hill, M. D., Manns, B., McGrail, K., O'Neill, B., Greiver, M., Froentjes, L. S., Manca, D. P., Mangin, D., Wong, S. T., MacLea Tags: Open access, Cardiovascular medicine Source Type: research

Single Versus Multiple Arterial Revascularization in Patients With Reduced Renal Function: Long-term Outcome Comparisons in 23,406 CABG Patients From Ontario, Canada
Objective: To compare the long-term outcomes of MAR versus SAR in patients with renal insufficiency. Summary of Background Data: Previous studies have been insufficiently powered to address whether MAR confers long-term benefit over SAR in patients with renal dysfunction who require CABG. Methods: We conducted retrospective cohort study in Ontario, Canada of patients who underwent isolated CABG (n = 23,406). The primary outcome was MACE, defined as the composite of stroke, myocardial infarction, and repeat revascularization. We compared patients by matching them on the propensity to have received SAR vers...
Source: Annals of Surgery - February 5, 2022 Category: Surgery Tags: ORIGINAL ARTICLES Source Type: research

Long-Term Outcomes for Patients With Acute Coronary Syndrome and Nonvalvular Atrial Fibrillation
Short-term outcomes are worse for patients with acute coronary syndrome (ACS) with a history of nonvalvular atrial fibrillation (NVAF). However, long-term prognosis remains unclear. We linked administrative health databases to identify patients hospitalized with ACS (ST-elevation myocardial infarction [STEMI], non –STEMI [NSTEMI], and unstable angina) between 2008 and 2019 in Alberta, Canada. Patients were stratified according to history of NVAF before hospitalization. The primary outcome was a composite of all-cause mortality, hospitalization for myocardial infarction, or stroke at 3 years.
Source: The American Journal of Cardiology - January 7, 2022 Category: Cardiology Authors: Pishoy Gouda, Douglas C. Dover, Anamaria Savu, Kevin Bainey, Shaun G. Goodman, Robert Welsh, Padma Kaul, Roopinder Kaur Sandhu Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Prognosis and Clinical Results after Coronary Artery Bypass Operation in Young Patients Aged < 45 Years: Chances and Limitations of a New Therapy Option
Thorac Cardiovasc Surg DOI: 10.1055/s-0041-1736229Coronary artery bypass grafting (CABG) is the recommended type of revascularization procedure in patients with left main or three-vessel disease and is considered an alternative when percutaneous coronary intervention is not feasible. We evaluated registry data to obtain long-term outcome data.All patients ≤45 years in whom CABG was performed between 2009 and 2019 were selected from the Heart and Diabetes Center NRW, Germany. Cox regression analysis was applied to estimate the incidence risk of events after surgery.A total of 209 patients (81.8% male) were included. Mean ...
Source: The Thoracic and Cardiovascular Surgeon - November 22, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Wittlinger, Thomas Schramm, Ren é Bleiziffer, Sabine Rudolph, Volker Gummert, Jan Fritz Deutsch, Marcus-Andr é Tags: Original Cardiovascular Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Drug overdose and the risk of cardiovascular diseases: a nested case –control study
ConclusionsDrug overdose appears to be associated with increased risk of cardiovascular diseases.Graphic abstract
Source: Clinical Research in Cardiology - October 15, 2021 Category: Cardiology Source Type: research